Open AccessPrecision medicine for hepatocellular carcinoma: driver mutations and targeted therapy
Author(s) -
Xiaoxiao Ding,
Qing-Ge Zhu,
Shiming Zhang,
Lei Guan,
Ting Li,
Lei Zhang,
Shiyang Wang,
Wanli Ren,
Xuemei Chen,
Jing Zhao,
Lin Song,
Zhizhen Liu,
Yang Bai,
Bing He,
Huqin Zhang
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.18382
Subject(s) - hepatocellular carcinoma , medicine , precision medicine , targeted therapy , carcinogenesis , cancer research , mutation , oncology , bioinformatics , cancer , gene , biology , pathology , genetics
Hepatocellular carcinoma (HCC) is the third most frequent cause of tumor-related mortality and there are an estimated approximately 850,000 new cases annually. Most HCC patients are diagnosed at middle or advanced stage, losing the opportunity of surgery. The development of HCC is promoted by accumulated diverse genetic mutations, which confer selective growth advantages to tumor cells and are called "driver mutations". The discovery of driver mutations provides a novel precision medicine strategy for late stage HCC, called targeted therapy. In this review, we summarized currently discovered driver mutations and corresponding signaling pathways, made an overview of identification methods of driver mutations and genes, and classified targeted drugs for HCC. The knowledge of mutational landscape deepen our understanding of carcinogenesis and promise future precision medicine for HCC patients.